Medical Condition News

RSS

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Type 2 diabetes is characterized by unsatisfactory levels of glycated hemoglobin (HbA1c) for extended periods. An article published in the May 2010 edition of Postgraduate Medicine reports a proposal to shorten the total time spent with uncontrolled hyperglycemia by minimizing the number of steps along the treatment-intensification ladder. In doing so, patients would decrease their exposure to hyperglycemia and potentially improve long-term outcomes.

16 Jun 2010

Meningococcal disease in infants: A potentially difficult and serious diagnosis

An article published in the May 2010 edition of Postgraduate Medicine documents a case study where a previously healthy, 15-week-old male infant was misdiagnosed and died of meningococcal disease. Initially the patient showed signs of the common cold and was treated as such, but symptoms worsened and he was admitted to the hospital emergency department.

16 Jun 2010

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

16 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

Horizon Pharma, Inc., announced today that data from the Phase 3 U.S. registration study of LODOTRA, a circadian cytokine modulator and novel modified-release, low-dose prednisone tablet, showed a statistically significant improvement in American College of Rheumatology response criteria in patients with rheumatoid arthritis.

16 Jun 2010

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma.

16 Jun 2010

CAMFT listed in 2010 Associations Advance America Honor Roll

The California Association of Marriage and Family Therapists has been named to the 2010 Associations Advance America Honor Roll, a national awards competition sponsored by the American Society of Association Executives & The Center for Association Leadership, Washington, D.C.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

MainStreet Monitoring Devices announces cause marketing partnership with Special Olympics Massachusetts

MainStreet Monitoring Devices, Inc., an innovator of superior personal safety, telemedicine and wireless health solutions to advance the care and protection of children and seniors, today announces its marketing partnership with Special Olympics Massachusetts on the eve of the 2010 Summer Games. MainStreet MD will donate a portion of its proceeds in support of more than 2200 Special Olympics athletes expected to compete in the Summer Games scheduled June 18-20, at Harvard University.

16 Jun 2010

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM™, showed the clinical efficacy of epratuzumab in patients with SLE.

16 Jun 2010

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia.

16 Jun 2010

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Report on treatment trends in systemic lupus erythematosus

BioTrends is pleased to announce the upcoming publication of a new syndicated report, TreatmentTrends®: Systemic Lupus Erythematosus (SLE). This report will provide a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. during the first week in June.

16 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

UNC researchers study why surgery happens less often in blacks with lung cancer

A new study led by UNC researchers that looks at newly diagnosed lung cancer patients and follows them from diagnosis forward is one of the first to give reasons why patients don't go to lung surgery and why surgery happens less often in blacks.

16 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Physicians play stronger role in ensuring asthma patients don't waver in taking drugs: Researchers

Armed with the right information, physicians can play a stronger role in ensuring asthma patients don't waver in taking drugs proven to prevent asthma attacks, according to researchers at Henry Ford Hospital in Detroit.

16 Jun 2010

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.

16 Jun 2010

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

SNM's 2010 Image of the Year illustrates the potential of hybrid molecular imaging to provide precise information about the location and function of a condition known as "hyperparathyroidism." Researchers selected this image from more than 1,500 studies presented over the course of four days during SNM's 57th Annual Meeting in Salt Lake City.

16 Jun 2010

3 new genes in genetic research of suicidal behaviour

Three genes that have barely been studied to date have now provided fresh knowledge about patients with suicidal backgrounds. This is the result of a study by a team of Spanish researchers at Mount Sinai Hospital and Columbia University in the City of New York (United States), which found that several mutations are involved. This finding could help to develop future genetic tests to identify predisposition to suicide, without ignoring the importance of social and cultural factors.

16 Jun 2010

Medical Condition News

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Meningococcal disease in infants: A potentially difficult and serious diagnosis

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

Phase 3 U.S. registration study of LODOTRA shows improvement in patients with RA

RG7204 holds promise for metastatic melanoma with V600E BRAF mutation

CAMFT listed in 2010 Associations Advance America Honor Roll

Stress-related psychiatric disorders more common among women: Study

MainStreet Monitoring Devices announces cause marketing partnership with Special Olympics Massachusetts

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Report on treatment trends in systemic lupus erythematosus

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

UNC researchers study why surgery happens less often in blacks with lung cancer

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Physicians play stronger role in ensuring asthma patients don't waver in taking drugs: Researchers

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

3 new genes in genetic research of suicidal behaviour

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News